Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model

Simple item page
dc.contributor.authorCasquero-Veiga, Marta
dc.contributor.authorGarcía-García, David
dc.contributor.authorPérez-Caballero, Laura
dc.contributor.authorTorres-Sánchez, Sonia
dc.contributor.authorBerrocoso, Esther
dc.contributor.authorDesco, Manuel
dc.contributor.authorSoto-Montenegro, María Luisa
dc.contributor.authorMac-Dowell Mata, Karina Soledad
dc.contributor.authorFraguas Herráez, David
dc.contributor.authorLeza Cerro, Juan Carlos
dc.contributor.authorArango López, Celso
dc.date.accessioned2024-01-30T19:08:01Z
dc.date.available2024-01-30T19:08:01Z
dc.date.issued2019-07
dc.description.abstractInflammation and oxidative stress (IOS) are considered key pathophysiological elements in the development of mental disorders. Recent studies demonstrated that the antipsychotic risperidone elicits an antiinflammatory effect in the brain. We administered risperidone for 2-weeks at adolescence to assess its role in preventing brain-related IOS changes in the maternal immune stimulation (MIS) model at adulthood. We also investigated the development of volumetric and neurotrophic abnormalities in areas related to the HPA-axis. Poly I:C (MIS) or saline (Sal) were injected into pregnant Wistar rats on GD15. Male offspring received risperidone or vehicle daily from PND35-PND49. We studied 4 groups (8-15 animals/group): Sal-vehicle, MIS-vehicle, Sal-risperidone and MIS-risperidone. [18F]FDG-PET and MRI studies were performed at adulthood and analyzed using SPM12 software. IOS and neurotrophic markers were measured using WB and ELISA assays in brain tissue. Risperidone elicited a protective function of schizophrenia-related IOS deficits. In particular, risperidone elicited the following effects: reduced volume in the ventricles and the pituitary gland; reduced glucose metabolism in the cerebellum, periaqueductal gray matter, and parietal cortex; higher FDG uptake in the cingulate cortex, hippocampus, thalamus, and brainstem; reduced NFκB activity and iNOS expression; and increased enzymatic activity of CAT and SOD in some brain areas. Our study suggests that some schizophrenia-related IOS changes can be prevented in the MIS model. It also stresses the need to search for novel strategies based on anti-inflammatory compounds in risk populations at early stages in order to alter the course of the disease.
dc.description.departmentDepto. de Farmacología y Toxicología
dc.description.departmentDepto. de Medicina Legal, Psiquiatría y Patología
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipMinisterio de Ciencia, Innovación y Universidades
dc.description.sponsorshipInstituto de Salud Carlos III
dc.description.sponsorshipCIBERSAM
dc.description.sponsorshipERDF
dc.description.sponsorshipDelegación del Gobierno para el Plan Nacional sobre Drogas
dc.description.sponsorshipFundación Alicia Koplowitz
dc.description.sponsorshipMadrid Regional Government
dc.description.statuspub
dc.identifier.citationCasquero-Veiga M, García-García D, MacDowell KS, Pérez-Caballero L, Torres-Sánchez S, Fraguas D, Berrocoso E, Leza JC, Arango C, Desco M, Soto-Montenegro ML. Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model. Eur Neuropsychopharmacol. 2019 Jul;29(7):880-896. doi: 10.1016/j.euroneuro.2019.05.002. PMID: 31229322.
dc.identifier.doi10.1016/j.euroneuro.2019.05.002
dc.identifier.issn0924-977X
dc.identifier.officialurlhttps://www.sciencedirect.com/science/article/pii/S0924977X19302500
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/31229322/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/96795
dc.issue.number7
dc.journal.titleEuropean Neuropsychopharmacology
dc.language.isoeng
dc.page.final896
dc.page.initial880
dc.publisherElsevier
dc.relation.projectIDPI14/00860
dc.relation.projectIDCPII14/00005
dc.relation.projectIDMV15/00002
dc.relation.projectIDPI17/01766
dc.relation.projectIDPNSD2017/085
dc.relation.projectIDFAK16/01
dc.relation.projectIDBRADE-CM S2013
dc.relation.projectIDICE-2958
dc.relation.projectIDB2017/BMD-3740 AGES-CM-2
dc.relation.projectIDSAF16-75500-R
dc.relation.projectIDFP7-HEALTH-2009-2.2.1-2-241909
dc.relation.projectIDFP7-HEALTH-2009-2.2.1-3-242114
dc.relation.projectIDFP7- HEALTH-2013-2.2.1-2-603196
dc.relation.projectIDFP7-HEALTH-2013-2.2.1-2-602478
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsrestricted access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.cdu615.21
dc.subject.cdu616.89-007
dc.subject.cdu615.01/.03
dc.subject.cdu615.214
dc.subject.cdu612.8
dc.subject.keywordDopamine antagonist
dc.subject.keywordFDG-PET
dc.subject.keywordInflammation/oxidonitrosative stress
dc.subject.keywordPoly I:C
dc.subject.keywordRisperidone
dc.subject.keywordSchizophrenia
dc.subject.ucmCiencias Biomédicas
dc.subject.unesco24 Ciencias de la Vida
dc.titleRisperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model
dc.typejournal article
dc.type.hasVersionAM
dc.volume.number29
dspace.entity.typePublication
relation.isAuthorOfPublicationd7de3e71-d141-4e63-ab4c-a71249846532
relation.isAuthorOfPublication51f079e8-b6f7-4209-93ec-361a2c3b083a
relation.isAuthorOfPublication60ff0835-366b-4a2b-9c1e-4533824ea881
relation.isAuthorOfPublication23fb749e-1a82-4838-8fea-01d964b22093
relation.isAuthorOfPublication.latestForDiscoveryd7de3e71-d141-4e63-ab4c-a71249846532
Download
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMID 31229322 in press.pdf
Size:
3.04 MB
Format:
Adobe Portable Document Format
Download
Collections
Artículos